TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31257044

Group type: EXPERIMENTAL
Intervention: Buzzy (MMJ Labs, Atlanta, GA)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: ShotBlocker (Bionix Development Corporation, Toledo, OH)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bubble-blowing
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 28619310

Group type: EXPERIMENTAL
Intervention: 20, 1-hour dancing classes over 10 weeks (n=15)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care control group (n=12)
Number of subjects: 27
Study: 26379122

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy with support to taper and/or discontinue antidepressant medication (MBCT-TS)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Maintenance antidepressant medication (m-ADM)
Number of subjects: 424
Study: 24089294

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic Clopidogrel
Number of subjects: 0
Study: 21872277

Group type: EXPERIMENTAL
Intervention: Sublobar resection (SR)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Segmental resection
Number of subjects: 222
Study: 19217669

Group type: EXPERIMENTAL
Intervention: Various treatment protocols
Number of subjects: 162
Study: 17353577

Group type: EXPERIMENTAL
Intervention: High phytate (HP) diet (P:Zn molar ratio = 23) for 9 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Lower phytate (LP) diet (P:Zn molar ratio = 10) for 9 days after a wash-out period
Number of subjects: 17
Study: 15179168

Group type: EXPERIMENTAL
Intervention: High dose ATP (225 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low dose ATP (150 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 11837981

Group type: EXPERIMENTAL
Intervention: 3.4 g/d of highly concentrated very long chain n‐3 PUFA after CABG
Number of subjects: 610

Group type: COMPARATOR
Intervention: Very long chain n‐3 PUFA 5.1-8.0 g/d after PTCA
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: 3.4-5.7 g/d of very long chain n‐3 PUFA after heart transplantation
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: 5.1 g/d of very long chain n‐3 PUFA
Number of subjects: 610
Study: 9113569

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (normal eyes of myopic patients)
Number of subjects: 31
Study: 8246581

Group type: EXPERIMENTAL
Intervention: Normothermic perfusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hypothermic perfusion
Number of subjects: 30
Study: 3818036

Group type: EXPERIMENTAL
Intervention: Aerua lanata extract (200 ml of 50 g/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerua lanata extract (100 g/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coriander (Coriandrum sativum) extract (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raw flowers of Aerua lanata
Number of subjects: 0
Study: 30814121

Group type: EXPERIMENTAL
Intervention: Colonoscopy with computer-aided diagnosis (AI system)
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 1058
Study: 28682892

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral nerve block with ropivacaine 0.2% and 0.3mg buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Femoral nerve block with ropivacaine 0.2% only
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.3mg buprenorphine subcutaneously
Number of subjects: 0
Study: 26244949

Group type: EXPERIMENTAL
Intervention: Enteral paracetamol (15mg/kg/dose 6 hourly for 7 days)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Intravenous indomethacin (0.2 mg/kg/dose once daily for 3 days)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 77
Study: 23766638

Group type: EXPERIMENTAL
Intervention: Computer-assisted errorless learning-based memory training program (CELP)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Therapist-led errorless learning program (TELP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 19
Study: 21340182

Group type: EXPERIMENTAL
Intervention: Low-intensity ultrasound therapy (LIUST)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control-placebo (CP)
Number of subjects: 26
Study: 18359179

Group type: EXPERIMENTAL
Intervention: CT angiograms using a medium-smooth kernel (B30s)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CT angiograms using a sharp kernel (B60s)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 20
Study: 17568241

Group type: COMPARATOR
Intervention: Increased mean low-density lipoprotein (LDL) diameter
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Increased large LDL particle concentration
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) increase of 10 mmHg
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Mean LDL diameter increase of 1 nm
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Large LDL particle concentration increase of 100 nmol/l
Number of subjects: 6105

Group type: COMPARATOR
Intervention: C-reactive protein (CRP) levels
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Soluble vascular cell adhesion molecule 1 (sVCAM-1) levels
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Homocysteine levels
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Amino-terminal-pro-B-type natriuretic peptide (NT-proBNP) levels
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Renin levels
Number of subjects: 6105
Study: 14597482

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control
Number of subjects: 55
Study: 11824893

Group type: EXPERIMENTAL
Intervention: MVCarbo regimen (mitomycin C, vinblastine, and carboplatin)
Number of subjects: 43
Study: 10332320

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Diazepam plus ibuprofen
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 8335426

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg administered twice daily with meals
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pravastatin 20 mg administered twice daily one hour before meals
Number of subjects: 24
Study: 2868254

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study: 2508737

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (5‐fluorouracil, adriamycin and mitomycin C)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 436

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 436
Study: 29791925

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 22
Study: 28323950

Group type: COMPARATOR
Intervention: Light-intensity walking interruptions (LW)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Simple resistance activity interruptions (SRA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Uninterrupted sitting (SIT)
Number of subjects: 21
Study: 25322868

Group type: EXPERIMENTAL
Intervention: Wii group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: XaviX group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Motivation across groups
Number of subjects: 24
Study: 23980348

Group type: EXPERIMENTAL
Intervention: Jinshuibao Capsule (JC) + losartan potassium
Number of subjects: 106

Group type: COMPARATOR
Intervention: losartan potassium
Number of subjects: 106
Study: 21562484

Group type: EXPERIMENTAL
Intervention: Ketanserin 50 mg - MDMA 75 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pindolol 20 mg - MDMA 75 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo - MDMA 75 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo - Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pindolol 20 mg - Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ketanserin 50 mg - Placebo
Number of subjects: 17
Study: 19447800

Group type: EXPERIMENTAL
Intervention: Sivelestat (0.3 mg/kg/h intravenous)
Number of subjects: 20
Study: 17045014

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once per day
Number of subjects: 221

Group type: COMPARATOR
Intervention: Ipratropium 2 puffs qid
Number of subjects: 221
Study: 12766750

Group type: EXPERIMENTAL
Intervention: Intravenous calcium chloride, n = 13
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo, n = 16
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (calcium and placebo)
Number of subjects: 29
Study: 10840101

Group type: EXPERIMENTAL
Intervention: Transurethral vaporization resection of the prostate (TUVRP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard transurethral prostatectomy (TURP)
Number of subjects: 68
Study: 9171125

Group type: EXPERIMENTAL
Intervention: AWR with low-pressure pneumoperitoneum (5 mmHg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional pneumoperitoneum (15 mmHg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 1287557

Group type: EXPERIMENTAL
Intervention: Prenatal thyrotropin-releasing hormone (TRH) treatment (400 micrograms i.v. every 8 h, one to four doses) plus 12 mg betamethasone (one or two doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prenatal thyrotropin-releasing hormone (TRH) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (saline plus betamethasone)
Number of subjects: 0
Study: 4032390

Group type: EXPERIMENTAL
Intervention: Acupuncture at loci SP6 and LI4
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no preparation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 20
Study: 29533397

Group type: EXPERIMENTAL
Intervention: Same-day single dose of low-volume (SSL) polyethylene glycol (PEG)
Number of subjects: 940

Group type: COMPARATOR
Intervention: Standard regimen (split dose of 4L PEG)
Number of subjects: 940
Study: 26564575

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NEMEX) program, performed in groups twice weekly for 8 weeks, consisting of 11 exercises focusing on joint stability and neuromuscular control.
Number of subjects: 0
Study: 24917452

Group type: EXPERIMENTAL
Intervention: Volume-time curve technique
Number of subjects: 450

Group type: COMPARATOR
Intervention: MOV technique
Number of subjects: 450
Study: 23416449

Group type: EXPERIMENTAL
Intervention: Multivoxel pattern analyses on fMRI data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatially distinct areas of the medial orbitofrontal cortex
Number of subjects: 0
Study: 19786722

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (BTIs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study: 18256460

Group type: EXPERIMENTAL
Intervention: Ziyuglycoside I (50 muM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation containing ziyuglycoside I
Number of subjects: 0
Study: 16185242

Group type: EXPERIMENTAL
Intervention: Trained teachers diagnosing presumptive malaria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trained teachers treating diagnosed cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-packaging of antimalarial drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-packaging of chloroquine
Number of subjects: 0
Study: 12363118

Group type: EXPERIMENTAL
Intervention: Standardized stepwise drug treatment regimen (SSTR)
Number of subjects: 248
Study: 9520889

Group type: EXPERIMENTAL
Intervention: Home based rehabilitation program (27 patients)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Clinic based rehabilitation program (27 patients)
Number of subjects: 54
Study: 7650502

Group type: EXPERIMENTAL
Intervention: Computer note-taking by Physician B
Number of subjects: 60

Group type: COMPARATOR
Intervention: Handwritten note-taking by Physician A
Number of subjects: 60
Study: 2667628

Group type: EXPERIMENTAL
Intervention: Kobayashi silicone cup ventouse
Number of subjects: 264

Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 264
Study: 60209

Group type: EXPERIMENTAL
Intervention: Initial oral dose of 900 mg propafenon
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral dose of 300 mg propafenon at eight-hourly intervals
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1.0-1.5 mg propafenon per kg body weight by quick infusion
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propafenon administered synchronously by the oral route
Number of subjects: 34
Study: 30971234

Group type: EXPERIMENTAL
Intervention: Holistic physical exercise training intervention once weekly for 15 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Holistic physical exercise training intervention
Number of subjects: 31
Study: 30480213

Group type: EXPERIMENTAL
Intervention: Video self-assessment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 16
Study: 27427132

Group type: EXPERIMENTAL
Intervention: Diet plan containing 1,500mg of sodium providing 2,000 calories, advised not to consume sodium-rich foods.
Number of subjects: 1492

Group type: COMPARATOR
Intervention: Routine diet (control group), advised not to consume sodium-rich foods.
Number of subjects: 1492

Group type: COMPARATOR
Intervention: Comparison between intervention and control groups.
Number of subjects: 1492
Study: 25188356

Group type: EXPERIMENTAL
Intervention: Complex working memory training program incorporating verbal and spatial tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 22946673

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Pregabalin with associated treatments (antidepressants and mood stabilizers)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Pregabalin with benzodiazepines
Number of subjects: 114
Study: 19174803

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermal ablation (RF)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Percutaneous ethanol injection (PEI)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermal ablation (RF) and Percutaneous ethanol injection (PEI)
Number of subjects: 701
Study: 17497466

Group type: EXPERIMENTAL
Intervention: Prednisolone plus Losartan (PSL + LST)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Prednisolone alone (PSL)
Number of subjects: 38
Study: 15764256

Group type: EXPERIMENTAL
Intervention: Losartan (25 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combined therapy (Losartan 25 mg and Enalapril 10 mg)
Number of subjects: 54
Study: 12476017

Group type: EXPERIMENTAL
Intervention: KET 2% shampoo
Number of subjects: 343

Group type: COMPARATOR
Intervention: ZPT 1% shampoo
Number of subjects: 343
Study: 9667559

Group type: EXPERIMENTAL
Intervention: Contour technique
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Manual outlining method
Number of subjects: 16
Study: 7814827

Group type: EXPERIMENTAL
Intervention: Zimeldine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Norzimeldine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: CPP 200
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (Zimeldine without HSS symptoms)
Number of subjects: 55
Study: 2787289

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 55

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 55
Study: 59017

Group type: EXPERIMENTAL
Intervention: Human diploid cell strain rabies vaccine (0.4 ml on day 0)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Human diploid cell strain rabies vaccine (0‐1 ml on days 0, 1, 2, 3)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Human diploid cell strain rabies vaccine (0‐1 ml on days 0, 3, 7, and 14)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Human diploid cell strain rabies vaccine (0.1 ml into each limb on day 0)
Number of subjects: 114
Study: 31239644

Group type: EXPERIMENTAL
Intervention: Etomidate (Group E, n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol (Group P, n=40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Etomidate (Group E)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol (Group P)
Number of subjects: 80
Study: 25267551

Group type: EXPERIMENTAL
Intervention: Marginal mean models fit with generalized estimating equations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard generalized estimating equation sandwich variance estimator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small-sample corrections to generalized estimating equations
Number of subjects: 0
Study: 25873101

Group type: EXPERIMENTAL
Intervention: Usual care plus acupuncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 24038728

Group type: EXPERIMENTAL
Intervention: 50 mg of d‐cycloserine (DCS) administered 1 hr prior to sessions 3‐7, n = 87
Number of subjects: 169

Group type: COMPARATOR
Intervention: Pill placebo administered 1 hr prior to sessions 3‐7, n = 82
Number of subjects: 169
Study: 20410904

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Number of subjects: 249

Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 249
Study: 20031809

Group type: EXPERIMENTAL
Intervention: Group-based psychosocial intervention program (20 sessions over a year)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Group-based psychosocial intervention program
Number of subjects: 237
Study: 17178485

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 1 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ketoprofen 100 mg
Number of subjects: 90
Study: 15064254

Group type: COMPARATOR
Intervention: Standard information leaflet about anaesthesia (Group 1)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Standard leaflet plus manufacturers' patient information leaflets for propofol and remifentanil (Group 2)
Number of subjects: 85
Study: 11791892

Group type: EXPERIMENTAL
Intervention: FP-spacer: fluticasone pressurised metered dose inhaler (Flixotide 250 microg ex-valve per actuation), eight puffs via a primed Volumatic 750-ml spacer.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: FP-neb: Flixotide Nebule 2 mg/2 ml via Pari LC Plus nebuliser.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo nebuliser
Number of subjects: 14
Study: 9230825

Group type: EXPERIMENTAL
Intervention: Latanoprost (50 mg/L)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate (8 mg/mL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Latanoprost and Physostigmine combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1773364

Group type: EXPERIMENTAL
Intervention: Alfentanil administered a few seconds before propofol injection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alfentanil administered just after propofol injection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bolus injection of alfentanil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dosages of alfentanil in plasma
Number of subjects: 40
Study: 6119510

Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 107
Study: 30442084

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block before fistula surgery
Number of subjects: 105

Group type: COMPARATOR
Intervention: Stellate ganglion block after surgery
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group without any block
Number of subjects: 105
Study: 29025888

Group type: EXPERIMENTAL
Intervention: Erdosteine 300 mg twice daily
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study: 26703279

Group type: EXPERIMENTAL
Intervention: Sustained-release dexamethasone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25410076

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin, 50 IU, subcutaneous injection, 1 time a day for 15 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin, 50 IU, subcutaneous injection, 1 time every 2 days for 30 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin, 50 IU, subcutaneous injection, 1 time every 3 days for 90 days
Number of subjects: 0
Study: 22641256

Group type: EXPERIMENTAL
Intervention: Bronchodilator therapy
Number of subjects: 12
Study: 20713478

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (10^8 colony‐forming units)
Number of subjects: 50
Study: 18346996

Group type: EXPERIMENTAL
Intervention: Hydrogel (n = 48)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (standard care, n = 23)
Number of subjects: 71
Study: 16167973

Group type: EXPERIMENTAL
Intervention: 2.2 g co-amoxiclav (or 2 g cefotaxime if penicillin-allergic)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 12207636

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRI)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCA)
Number of subjects: 350

Group type: COMPARATOR
Intervention: No antidepressants
Number of subjects: 350
Study: 10334546

Group type: EXPERIMENTAL
Intervention: Oral F‐AMP 50 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral F‐AMP 70 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral F‐AMP 90 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous F‐AMP 50 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous F‐AMP 25 mg/m2
Number of subjects: 18